Law360, New York (October 02, 2009) -- Biotechnology company Celldex Therapeutics Inc. has completed its purchase of fellow cancer drug maker Curagen Corp. for more than $90 million, the companies have announced.
The two companies have signed a definitive agreement to merge, allowing Curagen to become a wholly owned subsidiary of Celldex, a joint statement released Thursday said....
